Confidently Identify Rare Cancer Mutations with Clinical Decision Making Software

Cancer Cell-1

Download this application note to learn how a comprehensive database curated by experts can support clinical decision making in rare cancers, courtesy of QIAGEN.

New sequencing approaches, such as next-generation sequencing (NGS), have more clinical utility compared to conventional genetic testing tools, particularly for rare cancers.

The increased sensitivity of such approaches leads to a lot of data on genetic variants, requiring a database where each variant

  • is reliably annotated,
  • includes all of the known literature about it, and
  • is curated by expert oncologists and scientists
in order to understand the biological relevance and therapeutic actionability of patients' genetic profiles in rare cancers. 

Powerful software like QCI Interpret One does all of that to help understand the prognosis, diagnosis, and therapeutic options available for individuals with rare cancers.

Download the Resource

Confidently Identify Rare Cancer Mutations with Clinical Decision Making Software

QiagenLogo